Exelixis Inc risk profile
36 Normal where most of the sector sits
Measured 21 October 2026 from EXEL's filed statements. Recomputed nightly.
36 (Normal), driven by Concentration at 91, over 6 weighted categories on the MANUFACTURER profile.
What is measured
| Mechanism | Reading | Band | Direction | Driver |
|---|---|---|---|---|
| Market expectation | 24 | Normal | Stable | One-year price volatility — 35.9% |
| Operating pressure | 4 | Contained | Easing | Costs outgrowing revenue — -10.5 percentage points |
| Cash conversion | 23 | Normal | Stable | Cash conversion — 1.13x |
| Leverage and coverage | Reads total_debt, cash_and_cash_equivalents, ebitda, interest_expense, total_current_assets, total_current_liabilities and a disclosed CET1 ratio, for a bank or insurer. No reading is stored for this company. | |||
| Competitive position | 23 | Normal | Stable | Revenue-growth gap against peers — -3.2 percentage points |
| Concentration | 91 | Acute | Stable | Geographic concentration — 8,556 HHI |
These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.